

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

NCT05751525

Status RECRUITING
Sponsor Royal Devon and Exeter NHS Foundation Trust
Enrollment 21 participants

Key Eligibility Criteria

Inclusion (4)

- Current age e2 years
- Heterozygous for a V59M mutation in the KCNJ11 gene
- Successfully transferred to oral sulphonylurea therapy
- Willing to participate

Exclusion (2)

- Never able to transfer to oral sulphonylurea therapy
- Unwilling to participate

Locations (4 total)

University of Chicago, Chicago, Illinois, United States
University of Rome, Rome, Italy
University of Bergen, Bergen, Norway
... and 1 more locations